Review at Launch for New to Market Medications – Commercial Medical Benefit Drug Policyopen_in_new

UnitedHealthcare will review new‑to‑market, provider‑administered, FDA‑approved medications on its Review at Launch list and may exclude them from the medical benefit until a review and utilization management strategy is communicated; if approved, authorization is limited to the maximum FDA‑approved dose/frequency for up to six months. Providers must seek pre‑determination (strongly encouraged/required where applicable), document medical necessity per UHC P&T policy, FDA labeling, compendia and standard of care, and for biosimilars not in a policy must attest the biosimilar is expected to provide a superior clinical response; providers may not collect member payment for noncovered services without prior written consent.

"This drug policy applies to new medications that are: U."

Sign up to see full coverage criteria, indications, and limitations.